COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort.
Détails
ID Serval
serval:BIB_B0F93E870352
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort.
Périodique
British journal of clinical pharmacology
Collaborateur⸱rice⸱s
COVI-PREG and CONSIGN group
Contributeur⸱rice⸱s
Hadar E., Goncé A., Castillo K., Gratacós E., Poncelet C., Surita F., Dantas-Silva A., Luz A., Ribeiro-do-Valle C., Borrelli C., Quibel T., de Tejada B.M., Campelo S., Othenin-Girard V., Hcini N., Lambert V., Schäffer L., Hernadi A., Nieto-Calvache A.J., Sinisterra-Díaz S.E., Maya J., Pérez P.M., Bryon A.M., de Luca C., Etchegaray A., Moren J., Mousavi S.H., Qaderi S., Delsoz M., Eggel B., Geary M., Donnelly J., Kennelly M., Salameh F.T., Mccarthy C., Cleary B., Brugger R.C., Ko A., Reddy U., Grechukhina O., Fuenzalida J., Carvajal J., Johann S., Surbek D., Radan A.P., Raio L., Bernasconi M.T., Moser M., Deprest J., Richter J., Pinto P.V., Moucho M., Sichitiu J., Ville Y., Salomon L., Stirnemann J., Martinez A.R., Haratz K.K., Malinger G., Tallarek A.C., Hecher K., Schuler-Faccini L., Sanseverino MTV, Scherer M.H., Wender MCO, Oppermann MLDR, Bohrer B., Giuliani C., Friedrich L., Higgins M.F., Papadia A., Gasparri M.L., Morena A., Polli C., Taddei E., Nielsen-Saines K., Cambou M.C., Rao R., Mok T., Fajardo V., Mottet N., Garabedian C., Ghesquiere L., Kahlert C.R., Fischer T., Grawe C., Voekt C.A., Defert S., Dimet J., Böckenhoff P., Strizek B., Sentilhes L., Brot A., Mattuizzi A., Houssin C., Bassler D., Weber B., Rossier M.C., Mathis J., Ha E., Eggemann C., Bloch A., Netto R., Kaufmann M., Feuerschuette OHM, Breton B., Toussaint A., de Sa RAM, Elbahnasawy M., Abd-Elsalam S., Ducarme G., Pelerin H., Nafea A., Plantefeve G., le Parco C., Derouich M., Feki A., Grant G., Hoffmann I., Denize K., Canales M.G., Britschgi C., Kanellos P., Prentl E.B., Maisel J., Hoesli I., Monod C., Vetter G., Tirri B.F., Blume C., Kalimeris S., Brochut A.M., Sedille L., Martins I., Dos Camps D.A., Boulvain M., Leu S., Bütikofer K., Bernardes L.S., Dos Santos C.N., Micheletti B.H., Mosello J., Pereira N.G., Sturm S., Wardhana M.P., Dajti I., Al Kharouf F., Moreau C., Yin M., Haessig A., Ackermann S., Hernandez O., Aebi-Popp K., Masmejan S., Lepigeon K., Giannoni E.
ISSN
1365-2125 (Electronic)
ISSN-L
0306-5251
Statut éditorial
Publié
Date de publication
05/2023
Peer-reviewed
Oui
Volume
89
Numéro
5
Pages
1560-1574
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
The objective of this study was to describe the use of COVID-19-related medicines during pregnancy and their evolution between the early/late periods of the pandemic.
Pregnant women who tested positive for SARS-CoV-2 from March 2020 to July 2021 were included using the COVI-PREG registry. Exposure to the following COVID-19-related medicines was recorded: antibiotics, antivirals, hydroxychloroquine, corticosteroids, anti-interleukin-6 and immunoglobulins. We described the prevalence of medicines used, by trimester of pregnancy, maternal COVID-19 severity level and early/late period of the pandemic (before and after 1 July 2020).
We included 1964 pregnant patients who tested positive for SARS-CoV-2. Overall, 10.4% (205/1964) received at least one COVID-19-related medicine including antibiotics (8.6%; 169/1694), corticosteroids (3.2%; 62/1964), antivirals (2.0%; 39/1964), hydroxychloroquine (1.4%; 27/1964) and anti-interleukin-6 (0.3%; 5/1964). The use of at least one COVID-19-related medicine was 3.1% (12/381) in asymptomatic individuals, 4.2% (52/1233) in outpatients, 19.7% (46/233) in inpatients without oxygen, 72.1% (44/61) in those requiring standard oxygen, 95.7% (22/23) in those requiring high flow oxygen, 96.2% (25/26) in patients who required intubation and 57.1% (4/7) among patients who died. The proportion who received medicines to treat COVID-19 was higher before than after July 2020 (16.7% vs. 7.7%). Antibiotics, antivirals and hydroxychloroquine had lower rates of use during the late period.
Medicine use in pregnancy increased with disease severity. The trend towards increased use of corticosteroids seems to be aligned with changing guidelines. Evidence is still needed regarding the effectiveness and safety of COVID-19-related medicines in pregnancy.
Pregnant women who tested positive for SARS-CoV-2 from March 2020 to July 2021 were included using the COVI-PREG registry. Exposure to the following COVID-19-related medicines was recorded: antibiotics, antivirals, hydroxychloroquine, corticosteroids, anti-interleukin-6 and immunoglobulins. We described the prevalence of medicines used, by trimester of pregnancy, maternal COVID-19 severity level and early/late period of the pandemic (before and after 1 July 2020).
We included 1964 pregnant patients who tested positive for SARS-CoV-2. Overall, 10.4% (205/1964) received at least one COVID-19-related medicine including antibiotics (8.6%; 169/1694), corticosteroids (3.2%; 62/1964), antivirals (2.0%; 39/1964), hydroxychloroquine (1.4%; 27/1964) and anti-interleukin-6 (0.3%; 5/1964). The use of at least one COVID-19-related medicine was 3.1% (12/381) in asymptomatic individuals, 4.2% (52/1233) in outpatients, 19.7% (46/233) in inpatients without oxygen, 72.1% (44/61) in those requiring standard oxygen, 95.7% (22/23) in those requiring high flow oxygen, 96.2% (25/26) in patients who required intubation and 57.1% (4/7) among patients who died. The proportion who received medicines to treat COVID-19 was higher before than after July 2020 (16.7% vs. 7.7%). Antibiotics, antivirals and hydroxychloroquine had lower rates of use during the late period.
Medicine use in pregnancy increased with disease severity. The trend towards increased use of corticosteroids seems to be aligned with changing guidelines. Evidence is still needed regarding the effectiveness and safety of COVID-19-related medicines in pregnancy.
Mots-clé
Humans, Female, Pregnancy, COVID-19/epidemiology, SARS-CoV-2, Hydroxychloroquine/therapeutic use, Antiviral Agents/therapeutic use, Inpatients, Pregnancy Complications, Infectious/drug therapy, Pregnancy Complications, Infectious/epidemiology, COVID-19, COVID-19-related medicine, drug use, medicine use, pharmaco-epidemiology, pregnancy
Pubmed
Web of science
Création de la notice
28/11/2022 14:25
Dernière modification de la notice
03/12/2024 7:08
Données d'usage
